Angion Biomedica Corp.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Angion Biomedica Corp. - overview
Established
1998
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Founded in 1998 and based in New York, US, Angion Biomedica Corp. operates as a biotechnology company that develops small molecule targeting therapeutics to treat patients with acute kidney and lung injury related to transplantation COVID-19 related pneumonia. The company raised a total of four funding rounds, according to sec filings. This includes an IPO (Initial Public Offering) prospectus dated March 2014 that was withdrawn in October of the same year.
In February 2021, Angion Biomedica Corp. raised USD 117 million in pipe funding from Vifor Pharma Management Ltd. The company's medical R&D team focuses on discovering, developing, and commercializing small molecule therapeutics to treat acute organ injuries and chronic fibrotic diseases by understanding the HGF (hepatocyte growth factor) and fibrotic pathways involved in tissue repair and organ recovery. The product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor, and CYP11B2 Inhibitor.
The company plans to list on the Nasdaq global select market under the ticker symbol ANGN.
Current Investors
Formic Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.angion.com
Company Stage
PIPE
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.